作者
Alimuddin Zumla, Fu-Sheng Wang, Giuseppe Ippolito, Nicola Petrosillo, Chiara Agrati, Esam I Azhar, Chao Chang, Sherif A El-Kafrawy, Mohamed Osman, Laurence Zitvogel, Peter R Galle, Franco Locatelli, Ellen Gorman, Carlos Cordon-Cardo, Cecilia O’Kane, Danny McAuley, Markus Maeurer
发表日期
2020/7/1
来源
International Journal of Infectious Diseases
卷号
96
页码范围
431-439
出版商
Elsevier
简介
As of May 17th 2020, the novel coronavirus disease 2019 (COVID-19) pandemic has caused 307,395 deaths worldwide, out of 3,917,366 cases reported to the World Health Organization. No specific treatments for reducing mortality or morbidity are yet available. Deaths from COVID-19 will continue to rise globally until effective and appropriate treatments and/or vaccines are found. In search of effective treatments, the global medical, scientific, pharma and funding communities have rapidly initiated over 500 COVID-19 clinical trials on a range of antiviral drug regimens and repurposed drugs in various combinations. A paradigm shift is underway from the current focus of drug development targeting the pathogen, to advancing cellular Host-Directed Therapies (HDTs) for tackling the aberrant host immune and inflammatory responses which underlie the pathogenesis of SARS-CoV-2 and high COVID-19 mortality rates …
引用总数
20202021202220232024142214103